enGene Therapeutics Inc. (ENGN) Discusses Updated LEGEND Data and Regulatory Path for Detalimogene Transcript

🇨🇦 Seeking Alpha (CA) —

AI Summary

EnGene Therapeutics discussed updated LEGEND study data and the regulatory path for its drug candidate detalimogene. The transcript concerns clinical evidence and potential regulatory progress, though no specific findings are included in the provided description.

Markets Health EnGene Therapeutics detalimogene LEGEND study clinical data regulatory pathway biotechnology

Read original source →